Ginkgo Bioworks Holdings, Inc. (DNA) Income Statement
DNA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsDNA revenue and net income
Where DNA's revenue goes
2025Each bar shows an amount and its share of revenue. DNA kept −183.8% of revenue as net income.
DNA profit margins
DNA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −25.1% | −29.1% | +17.3% | — |
| Gross profit | −26.5% | −20.3% | +17.8% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
DNA quarterly EPS vs estimates
Ginkgo Bioworks beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.58).
DNA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M | $76.7M | $54.2M |
| Cost of revenue | $31.5M | $38.5M | $54.0M | $204.2M | $129.7M | $15.6M | $0 |
| Gross profit | $138.6M | $188.5M | $197.4M | $273.5M | $184.1M | $61.0M | $54.2M |
| Research & development | $243.8M | $424.1M | $580.6M | $1.05B | $1.15B | $159.8M | $96.3M |
| Sales, general & admin | $183.3M | $246.2M | $481.0M | $1.43B | $863.0M | $38.3M | $29.5M |
| Total operating expenses | $453.9M | $748.3M | $1.06B | $2.48B | $2.01B | $198.1M | $125.8M |
| Operating income | −$315.3M | −$559.8M | −$864.4M | −$2.21B | −$1.83B | −$137.0M | −$71.6M |
| Interest income | $22.6M | $38.6M | $57.2M | $20.3M | $837,000 | $2.6M | $5.8M |
| Interest expense | $0 | $94,000 | $93,000 | $106,000 | $2.4M | $2.4M | $2.4M |
| Income before taxes | −$313.6M | −$547.5M | −$892.9M | −$2.12B | −$1.84B | −$124.8M | −$119.8M |
| Income taxes | −$837,000 | −$479,000 | −$71,000 | −$15.0M | −$1.5M | $1.9M | $22,000 |
| Net income | −$312.8M | −$547.0M | −$892.9M | −$2.10B | −$1.83B | −$126.6M | −$119.3M |
| EBITDA | −$254.6M | −$484.4M | −$821.3M | −$2.08B | −$1.81B | −$108.6M | −$106.7M |
| EPS (diluted) | −$5.65 | −$7.56 | −$13.54 | −$47.84 | −$4.66 | −$3.93 | −$4.11 |
| Gross margin | 81.5% | 83.0% | 78.5% | 57.3% | 58.7% | 79.6% | 100.0% |
| Operating margin | −185.3% | −246.5% | −343.8% | −462.4% | −582.6% | −178.8% | −132.1% |
| Net margin | −183.8% | −240.9% | −355.1% | −440.6% | −583.1% | −165.2% | −220.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.2M | $19.5M | $33.4M | $38.8M | $49.6M | $48.3M | $43.8M | $89.0M | $56.2M | $37.9M | $34.8M | $55.4M |
| Cost of revenue | $1.7M | $15.9M | −$8.2M | $12.8M | $14.8M | $12.0M | $9.6M | $10.0M | $13.7M | $9.2M | $6.6M | $6.9M |
| Gross profit | $18.4M | $3.6M | $41.5M | $26.0M | $34.8M | $36.3M | $34.2M | $79.1M | $42.5M | $28.7M | $28.1M | $48.5M |
| Research & development | $46.2M | $49.9M | $50.1M | $69.4M | $53.4M | $70.9M | $76.4M | $77.0M | $134.2M | $136.5M | $117.0M | $156.7M |
| Sales, general & admin | $30.8M | $37.8M | $46.0M | $45.0M | $43.3M | $49.0M | $57.3M | $52.3M | $73.8M | $70.3M | $89.2M | $82.0M |
| Total operating expenses | $77.0M | $75.0M | $112.3M | $116.1M | $100.3M | $125.2M | $137.8M | $134.3M | $265.4M | $206.7M | $206.3M | $334.9M |
| Operating income | −$58.5M | −$71.4M | −$70.8M | −$90.0M | −$65.5M | −$89.0M | −$103.6M | −$55.2M | −$222.9M | −$178.0M | −$178.1M | −$286.4M |
| Interest income | $3.2M | $3.6M | $4.7M | $5.7M | $6.1M | $6.1M | $7.3M | $9.3M | $10.3M | $11.7M | — | $21.3M |
| Interest expense | — | — | — | — | — | — | $94,000 | — | — | — | $93,000 | — |
| Income before taxes | −$57.2M | −$76.1M | −$81.4M | −$80.8M | −$60.6M | −$90.9M | −$107.9M | −$56.8M | −$217.0M | −$165.9M | −$211.9M | −$302.9M |
| Income taxes | $128,000 | −$80,000 | −$643,000 | $1,000 | −$283,000 | $88,000 | −$325,000 | −$375,000 | $190,000 | $31,000 | −$198,000 | −$22,000 |
| Net income | −$46.7M | −$82.6M | −$80.8M | −$80.8M | −$60.3M | −$91.0M | −$107.5M | −$56.4M | −$217.2M | −$165.9M | −$211.7M | −$302.9M |
| EBITDA | −$44.4M | −$63.3M | −$67.7M | −$66.6M | −$46.1M | −$68.3M | −$143.5M | −$35.1M | −$140.7M | −$153.0M | −$288.9M | −$169.1M |
| EPS (diluted) | −$0.86 | −$1.39 | −$1.42 | −$1.45 | −$1.10 | −$1.68 | −$2.00 | −$1.08 | −$4.40 | −$0.08 | −$2.94 | −$3.65 |
| Gross margin | 91.5% | 18.4% | 124.4% | 67.0% | 70.1% | 75.1% | 78.1% | 88.8% | 75.6% | 75.7% | 81.0% | 87.5% |
| Operating margin | −290.5% | −366.5% | −211.9% | −231.8% | −132.1% | −184.1% | −236.3% | −62.0% | −396.7% | −469.1% | −512.5% | −516.7% |
| Net margin | −231.7% | −424.1% | −241.8% | −207.9% | −121.6% | −188.2% | −245.2% | −63.3% | −386.4% | −437.3% | −609.1% | −546.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in DNA's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
DNA financial results
In fiscal year 2025 (ended December 31, 2025), Ginkgo Bioworks reported revenue of $170.2 million, down 25.1% from the year before. It had a net loss of $312.8 million, a net profit margin of −183.8%. Diluted earnings per share came to −$5.65. Over five years revenue grew at an average rate of 17.3% a year.
See the DNA stock overview for the latest quote and news, or the DNA chart for price history and technical indicators.
DNA income statement FAQ
What is Ginkgo Bioworks's annual revenue?
Ginkgo Bioworks reported total revenue of $170.2 million for fiscal year 2025, which ended on December 31, 2025. That was down 25.1% from $227.0 million the previous year.
Is Ginkgo Bioworks profitable?
No. Ginkgo Bioworks reported a net loss of $312.8 million in fiscal 2025, a net profit margin of −183.8%; its operating margin was −185.3%.
What is Ginkgo Bioworks's gross margin?
Ginkgo Bioworks's gross margin was 81.5% in fiscal 2025: for every $100 of revenue, Ginkgo Bioworks kept $81 after the direct cost of its products and services.
How much does Ginkgo Bioworks spend on research and development?
Ginkgo Bioworks spent $243.8 million on research and development in fiscal 2025, 143.3% of revenue.
How fast is Ginkgo Bioworks growing?
Revenue grew 17.3% a year on average over the last five fiscal years, from $76.7 million to $170.2 million.
What are Ginkgo Bioworks's earnings per share?
Ginkgo Bioworks earned $-5.65 per diluted share in fiscal 2025, compared with $-7.56 a year earlier.
When will Ginkgo Bioworks report its next earnings?
Ginkgo Bioworks is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Ginkgo Bioworks's fiscal year end?
Ginkgo Bioworks's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.